These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 17620824)

  • 21. Parsonage-Turner syndrome: a rare case of abacavir hypersensitivity reaction in HIV-infected patients.
    Bellagamba R; Tommasi C; De Marco M; Narciso P
    J Infect; 2008 Jul; 57(1):88-90. PubMed ID: 18514915
    [No Abstract]   [Full Text] [Related]  

  • 22. Labeling changes for abacavir.
    AIDS Patient Care STDS; 2008 Aug; 22(8):683-4. PubMed ID: 18721055
    [No Abstract]   [Full Text] [Related]  

  • 23. Hypersensitivity reactions to HIV therapy.
    Chaponda M; Pirmohamed M
    Br J Clin Pharmacol; 2011 May; 71(5):659-71. PubMed ID: 21480946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA-B*5701 genetic screening prior to abacavir prescription in Georgia.
    Dvali N; Chkhartishvili N; Sharvadze L; Karchava M; Tsertsvadze T
    Georgian Med News; 2010 Dec; (189):16-20. PubMed ID: 21252404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetics and the potential for the individualization of antiretroviral therapy.
    Phillips EJ; Mallal SA
    Curr Opin Infect Dis; 2008 Feb; 21(1):16-24. PubMed ID: 18192781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care.
    De Spiegelaere W; Philippé J; Vervisch K; Verhofstede C; Malatinkova E; Kiselinova M; Trypsteen W; Bonczkowski P; Vogelaers D; Callens S; Ruelle J; Kabeya K; De Wit S; Van Acker P; Van Sandt V; Emonds MP; Coucke P; Sermijn E; Vandekerckhove L
    PLoS One; 2015; 10(4):e0123525. PubMed ID: 25874872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV.
    Quiros-Roldan E; Gardini G; Properzi M; Ferraresi A; Carella G; Marchi A; Malagoli A; Focà E; Castelli F
    Pharmacogenet Genomics; 2020 Oct; 30(8):167-174. PubMed ID: 32453265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abacavir hypersensitivity reaction.
    AIDS Patient Care STDS; 2002 May; 16(5):242. PubMed ID: 12058699
    [No Abstract]   [Full Text] [Related]  

  • 29. [HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance].
    Arnedo Valero M
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():34-9. PubMed ID: 18680694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Individualising HIV treatment--pharmacogenetics and immunogenetics.
    Telenti A; Aubert V; Spertini F
    Lancet; 2002 Mar; 359(9308):722-3. PubMed ID: 11888578
    [No Abstract]   [Full Text] [Related]  

  • 31. Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction?
    Bracciale L; Santangelo R; Fanti I; Prosperi M; Colafigli M; Di Giambenedetto S; Marchetti S; Di Franco A; Cauda R; De Luca A
    Antivir Ther; 2009; 14(1):99-101. PubMed ID: 19320242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.
    Airo P; Scarsi M; Malagoli A; Carella G; Izzo I; Carosi G; Torti C
    J Acquir Immune Defic Syndr; 2009 Jul; 51(3):361-2. PubMed ID: 19553774
    [No Abstract]   [Full Text] [Related]  

  • 33. Abacavir-induced agranulocytosis in two Taiwanese patients tested HLA-B*5701-negative.
    Chen SJ; Yang SP; Hung CC; Fung CP
    AIDS; 2010 May; 24(8):1238-9. PubMed ID: 20421748
    [No Abstract]   [Full Text] [Related]  

  • 34. Hypersensitivity reactions in patients treated with abacavir: strategies to avoid such reactions.
    Kapoor S
    AIDS Patient Care STDS; 2008 Oct; 22(10):769. PubMed ID: 18778242
    [No Abstract]   [Full Text] [Related]  

  • 35. 1592 (abacavir): do not rechallenge after hypersensitivity reaction.
    James JS
    AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HLA-Cw8 primarily associated with hypersensitivity to nevirapine.
    Gatanaga H; Yazaki H; Tanuma J; Honda M; Genka I; Teruya K; Tachikawa N; Kikuchi Y; Oka S
    AIDS; 2007 Jan; 21(2):264-5. PubMed ID: 17197830
    [No Abstract]   [Full Text] [Related]  

  • 37. HLA alleles and drug hypersensitivity reactions.
    Profaizer T; Eckels D
    Int J Immunogenet; 2012 Apr; 39(2):99-105. PubMed ID: 22136512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A study of HIV provider attitudes toward HLA-B 5701 testing in the United States.
    Watson ME; Patel LG; Ha B; Wannamaker P; Cuffe R; Shaefer M
    AIDS Patient Care STDS; 2009 Nov; 23(11):957-63. PubMed ID: 19839743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of abacavir hypersensitivity reactions in euroSIDA.
    Bannister WP; Friis-Møller N; Mocroft A; Viard JP; van Lunzen J; Kirk O; Gargalianos P; Bánhegyi D; Chiesi A; Lundgren JD;
    Antivir Ther; 2008; 13(5):687-96. PubMed ID: 18771052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenomics testing for type B adverse drug reactions to anti-infective drugs: the example of hypersensitivity to abacavir.
    Agundez JA; Esguevillas G; Amo G; Garcia-Martin E
    Recent Pat Antiinfect Drug Discov; 2014; 9(2):151. PubMed ID: 25891395
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.